Intraclot Recombinant Tissue-type Plasminogen Activator Reduces Perihematomal Edema and Mortality in Patients with Spontaneous Intracerebral Hemorrhage

The study aimed to investigate the impact of intraclot recombinant tissue-type plasminogen activator （rt-PA） on perihematomal edema （PHE） development in patients with intracerebral hemorrhage （ICH） treated with minimally invasive surgery （MIS） and the effects of intraclot rt-PA on the 30-day survival. We reviewed the medical records of ICH patients undergoing MIS between October 2011 and July 2013. A volumetric analysis was done to assess the change in PHE and ICH volumes at pre-MIS （T1）, post-MIS （T2） and day 10-16 （T3） following diagnostic computed tomographic scans （To）. Forty-three patients aged 52.8±11.1 years with （n=30） or without rt-PA （n=13） were enrolled from our institutional ICH database. The median rt-PA dose was 1.5 （1） mg, with a maximum dose of 4.0 mg. The ratio of clot evacuation was significantly increased by intraclot rt-PA as compared with controls （77.9%±20.4% vs. 64%±15%; P=0.046）. From TI to T2, reduction in PHE volume was strongly associ- ated with the percentage of clot evacuation （p=0.34; P=-0.027）. In addition, PHE volume was positively correlated with residual ICH volume at the same day （p ranging from 0.39-0.56, P〈0.01）. There was no correlation between the cumulative dose of rt-PA and early （T2） PHE volume （p=0.24; P=0.12） or de- layed （T3） PHE volume （p=0.19; P=0.16）. The 30-day mortality was zero in this cohort. In the selected cohort of ICH patients treated with MIS, intraclot rt-PA accelerated clot removal and had no effects on PHE formation. MIS aspiration and low dose of rt-PA seemed to be feasible to reduce the 30-day mor- tality in patients with severe ICH. A large, randomized study addressing dose titration and long-term outcome is needed.

Therapeutic effect of recombinant tissue plasminogen activator on acute cerebral infarction at different times

BACKGROUND:The study aimed to compare the therapeutic effect of recombinant tissue plasminogen activator(rt-PA) on the onset of acute cerebral infarction(ACI) at different time points of the first 6 hours.METHODS:A retrospective analysis was conducted in 74 patients who received rt-PA thrombolysis treatment within 4.5 hours after ACI and another 15 patients who received rt-PA thrombolysis treatment between 4.5-6 hours after ACI.RESULTS:National Institute of Health Stroke Scale(NIHSS) scores were statistically decreased in both groups(P>0.05) at 24 hours and 7 days after ACI.There was no significant difference in modified ranking scores and mortality at 90 days after the treatment between the two groups(P>0.05).CONCLUSIONS:The therapeutic effect and mortality of rt-PA treatment in patients with ACI between 4.5-6 hours after the onset of the disease were similar to those in patients who received rtPA within 4.5 hours after the onset of this disease.Therefore,intravenous thrombolytic therapy for ACI within 4.5-6 hours after ACI was effective and safe.

Recombinant Tissue Plasminogen Activator-conjugated Nanoparticles Effectively Targets Thrombolysis in a Rat Model of Middle Cerebral Artery Occlusion

The efficacy and safety of recombinant tissue plasminogen activator （rtPA） need to be improved due to its low bioavailability and requirement of large dose administration. The purpose of this study was to develop a fibrin-targeted nanoparticle （NP） drug delivery system for thrombosis combination therapy. We conjugated rtPA to poly（ethylene glycol）- poly（ε-caprolactone） （PEG-PCL） nanoparticles （rtPA-NP） and investigated its physicochemical characteristics such as particle size, zeta potential, enzyme activity of conjugated rtPA and its storage stability at 4℃. The thrombolytic activity of rtPA-NP was evaluated in vitro and in vivo as well as the half-life of rtPA-NP, the properties to fibrin targeting and its influences on systemic hemostasis in vivo. The results showed that rtPA-NP equivalent to 10% of a typical dose of rtPA could dissolve fibrin clots and were demonstrated to have a neuroprotective effect after focal cerebral ischemia as evidenced by decreased infarct volume and improved neurological deficit （P〈0.001）. RtPA-NP did not influence the in vivo hemostasis or coagulation system. The half-life of conjugated rtPA was shown to be approximately 18 times longer than that of free rtPA. These experiments suggested that rtPA-conjugated PEG-PCL nanoparticles might be a promising fibrin-targeted delivery system for a combination treatment of thrombosis.

Effects of Mercury on the Structure and Activity of BLM642-1290 Recombinant Helicase

Objective Bloom’s syndrome is an autosomal recessive disorder characterized by genomic instability and a predisposition to many cancers. Mutations of the BLM gene （encoding a BLM helicase） may form a structure of the etiology of this disease. As a global pollutant, mercury poses a major threat to human health. The current study was conducted to elucidate the effects of Hg^2＋ on the structure and activity of BLM642‐1290 recombinant helicase, and to further explore the molecular mechanisms of mercury toxicity to the DNA helicase. Methods The effects of Hg^2＋ on biological activity and structure of BLM642‐1290 recombinant helicase were determined by fluorescence polarized, ultraviolet spectroscopic, and free‐phosphorus assay technologies, respectively. Results The helicase activity, the DNA‐binding activity, and the ATPase activity of BLM642‐1290 recombinant helicase were inhibited by Hg^2＋ treatment. The LMCT （ligand‐to‐metal charge transition） peaks of the helicase were enhanced with the increase of the Hg^2＋ level. The LMCT peaks of the same concentration of helicase gradually increased over time. Conclusions The biological activity of BLM642‐1290 recombinant helicase is inhibited by Hg^2＋ treatment. The conformation of the helicase is significantly altered by Hg^2＋ . There exist two binding sites between Hg^2＋ and the helicase, which are located in the amino acid residues 1063‐1066 and 940‐944 of the helicase, respectively.

The Prokaryotic Expression and Bioactivity of the Recombinant Red Fire Ant Venom Allergen Sol i 4

The sting of red imported fire ant （RIFA） could cause serious allergic response in fraction of people. These allergic reactions are mainly caused by its venom, especially venom allergen Sol i 1-4. To produce large amount of RIFA venom allergen Sol i 4 for diagnosis of RIFA allergy and allergen-specific immunotherapy, the gene encoding this protein was amplified and cloned into the prokaryotic expression vector pET43, la. The recombinant plasmid was used to transform competent cells and the recombinant proteins were expressed in E. coll. SDS-PAGE and Western blotting analysis indicated that high-level expression of Sol i 4 protein was successfully achieved. Allergenic activity analysis of the recombinant allergen Sol i 4 was then performed on rabbit. The result showed that the recombinant protein obtained had significant allergenic activity. It indicated that the recombinant allergen Sol i 4 of RIFA venom was successfully expressed in E. coli, which provided foundation for further developing therapeutic and diagnosis reagents of RIFA allergy.

Analysis of Environmental Endocrine Disrupting Activities in Wastewater Treatment Plant Effluents Using Recombinant Yeast Assays Incorporated with Exogenous Metabolic Activation System

Objective To measure the endocrine disrupting chemicals （EDCs） in wastewater and evaluate the EDCs removal efficiencies in the municipal wastewater treatment plants （WWTP）. Methods A battery of in vitro recombinant yeast bioassays incorporated with exogenous metabolic activation system （rat liver preparation, S9 mix） was conducted to assess the estrogen receptor （ER）, androgen receptor （AR）, progesterone receptor （PR）, and thyroid receptor （TR） ant/agonistic activities of effluents collected from Datansha WWTP. Results The indirect estrogenic, anti‐androgenic, anti‐progesteronic, and anti‐thyroidic activities were observed in the influent. The removal efficiencies of EDCs were above 74%, suggesting that the present wastewater treatment processes were good enough to remove most of these indirect endocrine disrupting chemicals. Conclusion The incorporation of exogenous metabolic capacity into the test system was valid for the study of indirect effects on ER, AR, PR, and TR.

Expression of Recombinant Human Lysozyme-tachyplesin I(hLYZ-TP I)in Pichia Pastoris and Analysis of Antibacterial Activity

Antimicrobial peptides （AMPs） are making headlines in science because they demonstrate superior microbicidal characteristics compared to synthetic and semi-synthetic antibiotics.

Expression of the Phycoerythrin Gene of Gracilaria lemaneiformis (Rhodophyta) in E. coli and Evaluation of the Bioactivity of Recombinant PE

Phycoerythrin (PE) is one of the most important proteins involved in light capturing during photosynthesis in red algae. Its potential biological activities had gained wide concerns. In the present study, tumor cytotoxic and hydroxyl radical assay were preformed to detect the bioactivity of recombinant PE. Recombinant plasmids pGEX-PE and pBGL were transformed into E.coli BL21 to make two recombinant strains BEX (pGEX-PE) and BGL (pBGL). PE expressing in BEX (pGEX-PE) was validated by SDS-PAGE and Western blotting analysis. SDS-PAGE analysis indicated that the PE-GST fusion protein was mostly inclusion bod- ies. Specific expression of PE was confirmed by Western blotting analysis. The recombinant E. coli BEX (pGEX-PE) cells were col- lected and sonicated. The supernatants were reserved for the tumor cytotoxic experiments. The result of tumor cytotoxic assay indi- cated that the supernatants containing PE had the activity of inhibiting the growth of Hela cells and with the increase of protein con- centration, the inhibiting rate increased from 37.31% to 63.26%, which showed significant difference from the control. Hydroxyl radical scavenging effect was tested with supernatants of BEX (pGEX-PE) and BGL (pBGL) cell lysates treated with sonication and heating. For the sonication samples, the scavenging rates of the supernatants of BEX (pGEX-PE) and BGL (pBGL) cell lysates were significantly higher than the negative control BL21(pGEX-4T) (P<0.02), and the scavenging rates increased slowly following the increase of the protein content. For the heating samples, except for the 0.2 mg mL-1 BGL (pBGL) products, the scavenging effects of the supernatants of BEX (pGEX-PE) and BGL (pBGL) cell lysates were stronger than that of negative control BL21(pGEX-4T). However, the effect intensity was not positively correlated with the increase of the protein concentration. Though a partially de- creased hydroxyl radical scavenging activity was led by heating, the biological activity was still retained and conspicuous. This re- search showed that phycoerythrin protein expressing in E. coli has the potential medical and sanitarian value.

Antiviral Activity of Recombinant Cyanovirin-N against HSV-1

In this study,a standard strain of HSV-1 (strain SM44) was used to investigate the antiviral activity of the recombinant Cyanovirin-N (CV-N) against Herpes simplex virus type 1 (HSV-1) in vitro and in vivo.Cytopathic effect (CPE) and MTT assays were used to evaluate the effect of CV-N on HSV-1 in Vero cells.The number of copies of HSV-DNA was detected by real-time fluorescence quantitative PCR (FQ-PCR).The results showed that CV-N had a low cytotoxicity on Vero cells with a CC50 of 359.03±0.56 μg/mL,and that it could not directly inactivate HSV-1 infectivity.CV-N not only reduced the CPE of HSV-1 when added before or after viral infection,with a 50% inhibitory concentration (IC50) with 2.26 and 30.16μg/mL respectively,but it also decreased the copies of HSV-1 DNA in infected host cells.The encephalitis model for HSV-1 infection was conducted in Kunming mice,and treated with three dosages of CV-N (0.5,5 & 10 mg/kg) which was administered intraperitoneally at 2h,3d,5d,7d post infection.The duration for the appearance of symptoms of encephalitis and the survival days were recorded and brain tissue samples were obtained for pathological examination (HE staining).Compared with the untreated control group,in the 5mg/kg CV-N and 10mg/kg CV-N treated groups,the mice suffered light symptoms and the number of survival days were more than 9d and 14d respectively.HE staining also showed that in 5mg/kg CV-N and 10mg/kg CV-N treated groups,the brain cells did not show visible changes,except for a slight inflammation.Our results demonstrated that CV-N has pronounced antiviral activity against HSV-1 both in vitro and in vivo,and it would be a promising new candidate for anti-HSV therapeutics.

Rabies Virus Neutralizing Activity,Safety,and Immunogenicity of Recombinant Human Rabies Antibody Compared with Human Rabies Immunoglobulin in Healthy Adults

Objective Preliminary assessment of rabies virus neutralizing activity,safety and immunogenicity of a recombinant human rabies antibody(NM57)compared with human rabies immunoglobulin(HRIG)in Chinese healthy adults.Methods Subjects were randomly(1:1:1)allocated to Groups A(20 IU/kg NM57),B(40 IU/kg NM57),or C(20 IU/kg HRIG).One injection was given on the day of enrollment.Blood samples were collected on days-7 to 0(pre-injection),3,7,14,28,and 42.Adverse events(AEs)and serious AEs(SAEs)were recorded over a period of 42 days after injection.Results All 60 subjects developed detectable rabies virus neutralizing antibodies(RVNAs)(>0.05 IU/mL)on days 3,7,14,28,and 42.The RVNA levels peaked on day 3 in all three groups,with a geometric mean concentration(GMC)of 0.2139 IU/mL in Group A,0.3660 IU/mL in Group B,and0.1994 IU/mL in Group C.At each follow-up point,the GMC in Group B was significantly higher than that in Groups A and C.The areas under the antibody concentration curve over 0-14 days and 0-42 days in Group B were significantly larger than those in Groups A and C.Fifteen AEs were reported.Except for one grade 2 myalgia in Group C,the other 14 were all grade 1.No SAEs were observed.Conclusion The rabies virus neutralizing activity of 40 IU/kg NM57 was superior to that of 20 IU/kg NM57 and 20 IU/kg HRIG,and the rabies virus neutralizing activity of 20 IU/kg NM57 and 20 IU/kg HRIG were similar.Safety was comparable between NM57 and HRIG.

REGULATORY EFFECTS OF HUMAN RECOMBINANT IL-6 ON NATURAL KILLER CELL ACTIVITY OF HUMAN FETAL SPLEENS

In the present study it was proved first that human recombinant interleukin-6(HrIL-6) significantly augmented natural killer(NK) cell activity derived from human fetal spleens against K562 target cells in a 4 hours 51Cr release assay. The enhancement of NK activity with 24 hours preincubation in HrlL-6 was dose-dependent, and significantly higher than that of fresh NK cells and controls cultured with RPMI-1640 medium alone (P<0.001). We also found that IL-6 was able to augment NK activity from different fetal spleens at 20 to 40 weeks of gestation (up to 2.24 to 2.78 times), and no difference of NK activity of fetal splenocytes treated by HrIL-6 was observed between different fetal age (32.3% to 45.4%, P>0.05). Furthermore, IL-6-augmented NK activity of fetal splenocytes was very similar to adult levels (P>0.05). These finding strongly indicated that IL-6 plays an important role in the development of NK cell function during the gestational period, suggesting that IL-6 may be of importance in the regulation of host defense mechanisms against malignancies and viral diseases.

Preparation and analysis of immunocompetence of recombinant fusion protein of the immunodominant region in chlamydial protease-like activity factor from Chlamydophila pneumoniae and its application in serodiagnosis

To clone the gene coding the immunodominant region in the chlamydial protease-like activity factor(CPAF)from Chlamydophila pneumoniae,to analyze immunocompetence of the expressed protein, and to evaluate its value in serodiagnosis,the CPAF immunodominant region gene was amplified,ligated into a pGEX6p-2 vector,and then the expressed recombinant protein was purified with glutathione S- transferase(GST)agarose gel FF after renaturation,then identified by SDS-PAGE and Western blot.A new indirect ELISA was developed with the purified protein as coating antigen.The immunogenicity of the recombinant protein was evaluated by immunization to New Zealand rabbits,and its immunoreactivity was analyzed by reacting with anti-C,pneumoniae antibody.300 clinical sera samples were respectively de- tected by microimmunofluorescence(MIF)as reference method and the indirect ELISA,and the differ- ence between the two methods was analyzed.Cross-reactivity against Chlamydia trachomatis was investi- gated with the indirect ELISA to detect anti-C,trachomatis positive antisera.The results indicated that a 51.3 kDa recombinant protein was obtained.Western blot assay proved that the recombinant protein could merely specifically react with human anti-C.pneumoniae antisera.The titers of the specific IgG an- tibodies in the immunized New Zealand rabbits were above 1:16 000.Anti-C.pneumoniae IgG positive and negative reference sere were detected with the indirect ELISA,and the concordance rate of negative and positive results were both 100%(40/40).The sensitivity and specificity of the indirect ELISA in comparison with MIF were 93.8%(45/48)and 100%(252/252)separately by detecting 300 clinical sera samples,and the concordance rate between the two methods was 99.0%.No cross reaction against C.trachomatis was found with the indirect ELISA to detect anti-C,trachomatis positive antisera.In con- clusion,the prepared recombinant protein of the CPAF immunodominant region shows excellent immuno- competence and can be used to develop a new indirect ELISA as a method to detect anti-C.pneumoniae antibody for diagnosis of C.pneumoniae infection.

Efficacy of recombinant human osteoprotegerin combined with tinidazole in the treatment of periodontitis mice and its correlation with serum RANKL and MCP-1 levels

Objective: To investigate the effect of recombinant human osteoprotegerin combined with tinidazole on mice with periodontitis and the effect on serum RANKL and MCP-1 levels. Methods: 80 SPF-cleaned mice were randomly divided into 4 groups, 20 each, model group, tinidazole group and recombinant human osteoprotegerin group were modeled by Kimura et al., and tinidazole group received tinidazole. After intragastric administration, the recombinant human osteoprotegerin group was injected with recombinant human osteoprotegerin in the periodontal pocket according to the tinidazole group. The periodontal changes of the four groups of mice were observed and recorded, and the gingival rating was performed. Epithelial tissue morphology was observed by hematoxylin-eosin (HE) staining. Serum levels of IL-4, IL-6, RANKL and MCP-1 were measured by enzyme-linked immunosorbent assay. Results:After the intervention, the model group developed severe inflammatory reactions, including redness, hemorrhage, and deep periodontal pockets. The teeth were significantly loosened. The mice in the tinidazole group and the recombinant human osteoprotegerin group recovered substantially, and the gingival rating of the recombinant human osteoprotegerin group was better than that. The tinidazole group and the model group (P<0.05). The results of HE staining showed that the model group had edema, vasodilation and a large amount of inflammatory infiltration. The epithelial structure of the mice in the tinidazole group and the recombinant human osteoprotegerin group was intact and arranged closely and orderly. After intervention, the IL-4 in the tinidazole group and the recombinant human osteoprotegerin group was significantly higher than the model group and IL-6 was significantly lower than the model group (P<0.05), and the recombinant human osteoprotegerin group IL-4 was significantly higher after the intervention. IL-6 was significantly lower in the tinidazole group than in the tinidazole group (P<0.05). After the intervention, the tinidazole group and the recombinant human osteoprotegerin group were significantly reduced, and the recombinant human osteoprotegerin group RAKNL and MCP-1 were significantly lower than the model group (P>0.05). Conclusion: Recombinant human osteoprotegerin combined with tinidazole has a better therapeutic effect on gums and teeth in mice with periodontitis, and can lower the levels of RAKNL and MCP-1 in serum, inhibit bone resorption and protect teeth.

Kinetic studies on recombinant stem bromelain

Stem bromelain is a plant thiol protease with several industrial and therapeutic applications. This current work presents kinetic studies of recombinant bromelain (recBM) expressed in Escherichia coli BL21-AI on foursynthetic substrates, N-α-carbobenzoxy-L-alanyl-p-nitrophenylester (ZANPE), N-α-carbobenzoxy-L-arginyl-L-ar-ginine-p-nitroanilide (ZAANA), N-α-carbobenzo-xy-L-phenylalanyl-L-valyl-L-arginine-p-nitroanili-de (ZPVANA) and L-pyroglutamyl-L-phenylalanyl-L-leucine-p-nitroanilide (PFLNA). Hydrolytic activities of recBM at various pH and temperature conditions were compared to that of commercial bromelain (cBM). Both enzymes demonstrated high activities at 45o C and pH 5 - 8 for recBM and pH 6 - 8 for cBM. recBM showed marginally lower Kmand slightly higher kcat/Kmfor ZAANA, ZANPE and ZPVANA in comparison to cBM.trans Epoxysuccinyl-L-leucylamido {4- guanidino}butane (E-64) severely affected recBM and cBM hydrolysis of the synthetic substrates by competitive inhibition with Kivalues of 3.6 - 5.1 μM and 5.5 - 6.9 μM for recBM and cBM, respectively. The evaluated properties of recBM including temperature and pH optima, substrate specificity and sensitivity to inhibitors or activators, satisfy the requisites required for food industries.

Purification and Identification of Recombinant Alpha-bungarotoxin

[ Objective ] This paper aimed to obtain active alpha-bungarotoxin （α-BGT） protein and investigate the isolation and purification of recombinant α-BGT protein. [ Method] The expressed soluble fusion protein was purified by using GSTrap FF affinity columns. Purified fusion protein bound to GSTrap FF affinity col- umns was directly cleaved by thrombin to obtain the solution containing recombinant α-BGT. Using natural α-BGT as control, the antigenicity and biological activity of the purified fusion protein and recombinant α-BGT were detected by SDS-PAGE, Western Blot and toxicity test in vivo. [ Result] Recombinant ot-BGT was iso- lated; the purified fusion protein and recombinant α-BGT were similar to the natural α-BGT in antigenicity; the toxicity of purified fusion protein was relatively wea- ker; recombinant α-BGT was similar to the natural ot-BGT in toxicity. [Condusion] This study laid the foundation for further large-scale production of recombi- nant α-BGT.

Research on the Construction and Function of a Chlorophyll Degradation Recombinant Engineering Strain

In order to effectively reduce the chlorophyll content in flue-cured tobacco, improve the overall quality of tobacco leaves, chlorophyllase gene was cloned from Arabidopsis thaliana. After the expression of the expression vector in E. coli, the recombinant engineering strain was obtained. Afterwards, IPTG(isopropy-β-D-thiogalactopyranoside)was used to induce the goal protein, and the chlorophyllase activity of the recombinant engineering strain was measured, so as to investigate its degradation effect on the chlorophyll in the extracts of tobacco leaves. The results were as follows:(1) the amplified chlorophyllase gene AtCLH1 constructed the expression vector p ET28 a-At CLH1 successfully, obtaining the recombinant engineering strain;(2) induced under 30 ℃ for 22 h, the strain could well express the recombinant protein At CLH1 with 0.5 mmol/L IPTG, and the molecular weight was about 35 k Da;(3) the strain showed good chlorophyllase producing capability, and the activity of the produced chlorophyllase could reach up to 24.9 U/m L, which could degrade the chlorophyll in tobacco extract and had a good application prospect in improving the quality of low quality tobacco;(4) based on the results of orthogonal test, the enzyme extract from the strain was added to the tobacco leaf surface, which could make the degradation rate of chlorophyll in the tobacco leaf reach17.06% under the temperature of 37 ℃ at the humidity of 75% for 48 h;(5) after treated by the enzyme liquid, the test tobacco showed increase in the content of aromatic substances, enhancement of tobacco fragrance quality and amount, significant decrease of offensive odor and irritation, significant improvement of agreeable aftertaste, making the overall sensory quality of the tobacco leaf significantly improved.

重组组织型纤维蛋白溶酶原激活剂静脉溶栓后不同时间加用替罗非班对急性缺血性脑卒中患者神经血管功能的影响

目的探讨重组组织型纤维蛋白溶酶原激活剂(rt-PA)静脉溶栓后不同时间加用替罗非班对急性缺血性脑卒中(AIS)患者神经血管功能的影响。方法选择2020年3月至2023年3月北京老年医院神经内科收治的120例AIS患者为研究对象,患者均经rt-PA静脉溶栓治疗。根据静脉溶栓治疗后加用替罗非班的时间将患者分为早期组(溶栓后6 h内,n=52)、中期组(溶栓后6~12 h,n=38)和晚期组(溶栓后12~24 h,n=30)。比较治疗前、治疗后3组患者神经功能[美国国立卫生院卒中量表(NIHSS)评分、改良Rankin量表(mRS)评分]、血管功能[血管性假血友病因子(vWF)、血管内皮细胞钙黏蛋白(VE-cadherin)、血栓调节蛋白(TM)]、炎症因子[高敏C反应蛋白(hs-CRP)、同型半胱氨酸(Hcy)、白细胞介素-1β(IL-1β)]水平,记录治疗期间不良事件发生率。结果治疗前,3组患者NIHSS、mRS评分比较差异无统计学意义(P>0.05);3组患者治疗后NIHSS、mRS评分显著低于治疗前(P<0.05);治疗后,早期组患者NIHSS、mRS评分显著低于中期组、晚期组,中期组患者NIHSS、mRS评分显著低于晚期组(P<0.05)。治疗前,3组患者vWF、VE-cadherin、TM水平比较差异无统计学意义(P>0.05);3组患者治疗后vWF、VE-cadherin、TM水平显著低于治疗前(P<0.05);治疗后,早期组患者vWF、VE-cadherin、TM水平显著低于中期组、晚期组(P<0.05);治疗后,晚期组患者vWF水平显著高于中期组(P<0.05),中期组与晚期组患者VE-cadherin、TM水平差比较异无统计学意义(P>0.05)。治疗前,3组患者hs-CRP、Hcy、IL-1β水平比较差异无统计学意义(P>0.05),3组患者治疗后hs-CRP、Hcy、IL-1β水平显著低于治疗前(P<0.05);治疗后,早期组患者hs-CRP、Hcy、IL-1β水平显著低于中期组和晚期组,中期组患者hs-CRP、Hcy、IL-1β水平显著低于晚期组(P<0.05)。治疗期间,3组患者症状性脑出血发生率比较差异无统计学意义(P>0.05);早期组患者再闭塞、心肺并发症发生率显著低于中期组、晚期组(P<0.05);中期组与晚期组患者再闭塞、心肺并发症发生率比较差异无统计学意义(P>0.05)。结论rt-PA静脉溶栓后不同时间加用替罗非班后均可促进AIS患者神经功能、血管功能恢复,同时可抑制炎症反应,其中早期加用替罗非班效果最佳。

乳腺癌术后获得性血友病A的临床研究

目的 探讨1例乳腺癌术后获得性血友病A(AHA)的病因、临床表现、诊断与治疗过程,并通过检索文献,从实验室检查的角度出发,总结AHA的成因、诊断、治疗、预防等情况,以提高临床对AHA的认识。方法 分析该院2023年5月13日收治的1例乳腺癌术后患者创面渗血不止的原因,同时进行活化部分凝血活酶时间(APTT)纠正试验和凝血因子Ⅷ抑制物检测。以“获得性血友病A”“AHA”为关键词,对万方数据库和PubMed数据库2015-2024年发表的中文文献进行检索并分析。结果 该例患者APTT孤立性延长伴凝血因子Ⅷ∶C显著降低。APTT纠正试验提示患者存在时间温度依赖性凝血因子Ⅷ抗体,凝血因子Ⅷ抑制物滴度为1∶16.。该患者临床诊断为AHA,经注射重组活化人凝血因子Ⅶ止血,加用环磷酰胺清除凝血因子Ⅷ抑制物,患者血红蛋白水平逐渐稳定升高。文献检索结果发现,共检索到文献15篇,其中单病例报道的有10篇,多病例报道的有5篇,共涉及78个病例,其中无明确病因35例,自身免疫性疾病19例,约50%病例伴有基础疾病。结论 外科手术一定要重视凝血功能检测,对于孤立性APTT延长的患者,最好查找APTT延长的根本原因,同时临床要提高对AHA的识别、诊断和治疗水平。

禽致病性大肠杆菌HlyE蛋白的免疫原性研究

为评估禽致病性大肠杆菌(APEC)溶血素HlyE蛋白的免疫原性,本研究对APEC溶血素HlyE蛋白进行原核表达和纯化,并对表达的重组蛋白进行SDS-PAGE和western blot分析,将纯化蛋白利用透析袋在4℃透析后,利用血琼脂平板对其溶血活性进行检测。SDS-PAGE和western blot结果显示,表达并纯化到分子量约为36 ku的重组HlyE蛋白(rHlyE),经ND-2000超微量核酸蛋白测定仪测定纯化后蛋白浓度为0.65 mg/mL;溶血活性检测结果显示,rHlyE具有溶血活性。以透析后的rHlyE作为抗原,按照50μg/只的剂量免疫小鼠,对照组于相同时间点注射等量PBS,共免疫3次间隔14 d,并于首免后不同时间采血,采用间接ELISA方法检测两组小鼠血清特异性抗体水平,并于三免后18 d以2 LD_(50)的APEC菌液攻毒小鼠,观察7 d内小鼠的死亡情况;于首免后28 d剖杀各组小鼠取其脾脏制备脾淋巴细胞,采用流式细胞术分别检测CD3^(+)、CD4^(+)、CD8^(+)T淋巴细胞亚型比率,对rHlyE的免疫原性进行评估。间接ELISA检测结果显示,该蛋白能够诱导机体产生体液免疫应答,分泌高表达量的IgG抗体,抗体水平于三免后15 d达到最高水平。rHlyE免疫攻毒保护试验结果显示,免疫组小鼠基本无明显临床症状,7 d内存活率达80%;而对照组小鼠表现明显临床症状,于攻毒后3 d内全部死亡。流式细胞术结果显示,与对照组相比,免疫组小鼠的CD3^(+)、CD4^(+)和CD8^(+)T淋巴细胞亚型比率均升高。上述结果表明,rHlyE在大肠杆菌BL21中为部分可溶性表达,将其免疫小鼠后可诱导小鼠产生较高水平的体液免疫应答,并且可对小鼠产生较好的免疫保护效果。本研究明确了APEC HlyE蛋白的免疫原性,为APEC免疫保护蛋白的筛选以及疫苗研发提供了借鉴与参考。

依达拉奉右莰醇在高龄中重度急性缺血性脑卒中rt-PA静脉溶栓治疗中的应用时机

目的 探讨依达拉奉右莰醇在高龄中重度急性缺血性脑卒中(AIS)重组组织型纤溶酶原激活剂(rt-PA)静脉溶栓治疗中的应用时机。方法 选择rt-PA静脉溶栓救治的221例高龄中重度AIS患者,随机分为对照组70例、早期组75例、晚期组76例。对照组接受rt-PA静脉溶栓治疗,早期组在rt-PA静脉溶栓治疗启动后即刻给予依达拉奉右莰醇治疗,晚期组在rt-PA静脉溶栓24 h后给予依达拉奉右莰醇治疗。于治疗7 d时采用NIHSS评分评价神经功能改善情况,治疗90 d时采用mRS评分评价预后情况,比较三组短期疗效和长期疗效;观察24 h症状性颅内出血发生率、14 d颅外系统性并发症发生率和90 d病死率,比较三组治疗安全性。结果 三组7 d神经功能改善率、90 d预后良好率比较,早期组和晚期组均高于对照组,且早期组高于晚期组(P均<0.05)。三组24 h症状性颅内出血发生率、14 d颅外系统性并发症发生率比较,早期组低于晚期组和对照组(P均<0.05),晚期组与对照组比较差异无统计学意义(P>0.05)。三组90 d病死率比较,早期组和晚期组均低于对照组,且早期组低于晚期组(P均<0.05)。结论 高龄中重度AIS患者rt-PA静脉溶栓后即刻应用依达拉奉右莰醇可提高rt-PA静脉溶栓治疗的有效性和安全性,减少并发症的发生,改善患者预后。